Evidence map›Paper›PMID 36389061›Full record

ArticleFrontiers in aging neuroscience2022

Management of advanced Parkinson's disease in Israel: Clinicians viewpoint and action items.

Tanya Gurevich, David Arkadir, Samih Badarny, Sandra Benizri, Oren Cohen, Ruth Djaldetti, Sharon Hassin-Baer, Meir Kestenbaum, Zeev Nitsan, Yair Zlotnik and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Tanya GurevichMovement Disorders Unit, Tel Aviv Medical Center, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
David ArkadirDepartment of Neurology, Faculty of Medicine, Hadassah Medical Organization, Hebrew University, Jerusalem, Israel.
Samih BadarnyGalilee Medical Center, Naharyia, Israel.
Sandra BenizriMovement Disorders Unit, Assuta Ramat HaHayal Hospital, Tel Aviv, Israel.
Oren CohenSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ruth DjaldettiSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sharon Hassin-BaerSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Meir KestenbaumSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Zeev NitsanMovement Disorder Clinic, Barzilai Medical Center, Ashkelon, Israel.
Yair ZlotnikDepartment of Neurology, Movement Disorders Clinic, Soroka University Medical Center, Beersheba, Israel.
Gilad YahalomDepartment of Neurology, Movement Disorders Clinic, Shaare Zedek Medical Center, School of Medicine, Hebrew University, Jerusalem, Israel.
Tel Aviv University · ILAssaf Harofeh Medical Center · ILAssuta Medical Center · ILBarzilai Medical Center · ILHadassah Medical Center · ILShaare Zedek Medical Center · ILSoroka Medical Center · ILWestern Galilee Hospital · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is taking a staggering toll on healthcare systems worldwide, with the bulk of the expenditures invested in the late stages of the disease. Considering the rising life expectancy and the increasing prevalence of PD across the globe, a clear understanding of the early signs and treatment options available for advanced PD (APD), will facilitate tailoring management programs and support services. This task is complicated by the lack of both global consensus in defining APD and standardized care guidelines. This perspective prepared by a panel of movement disorder specialists, proposes to extend and optimize currently accepted PD coding to better reflect the diverse disease manifestations, with emphasis on non-motor features. The panel seeks to promote timely diagnosis by adjustment of evaluation tools for use by community neurologists and suggests modification of eligibility criteria for advanced therapy. Moreover, it advocates multidisciplinary assessments of APD patients to drive personalized, patient-centered and holistic management. Overall, earlier and more targeted intervention is expected to markedly improve patient quality of life.

Indexed as

advanced Parkinson’s diseaseburden on public health care systemsclinical challengesDelphi criteriaintensified device aided therapiesParkinson’s disease stage-appropriate healthcare facilitiespatient-centered holistic managementtailored management programs

Identifiers

PMID36389061
PMCPMC9647998
OpenAlexW4307634261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.